A5086341503- Vasculitis and related conditions
- Urticaria and Related Conditions
- Otitis Media and Relapsing Polychondritis
- Renal Diseases and Glomerulopathies
- Systemic Lupus Erythematosus Research
University Hospital Bonn
2023-2024
Abstract Background Glucocorticoids (GC) are the standard treatment for giant cell arteritis (GCA), even though they associated with adverse side effects and high relapse rates. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, has shown promise in sustaining remission reducing cumulative GC dosage, but it increases risk of infections is expensive. After discontinuation TCZ, only about half patients remain remission. Additionally, few studies have been conducted looking at...
Abstract • Background : Glucocorticoids (GC) are the standard treatment for giant cell arteritis (GCA), even though they associated with adverse side effects and high relapse rates. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, has shown promise in sustaining remission reducing cumulative GC dosage, but it increases risk of infections is expensive. After discontinuation TCZ, only about half patients remain remission. Additionally, few studies have been conducted looking at...
<h3>Background</h3> Giant cell arteritis (GCA) is the most common systemic vasculitis found in adults over 50 years of age and affects medium large vessels. The standard treatment glucocorticoids (GC). Because negative side effects GC high prevalence relapses should be combined with other immunosuppressive or immunomodulatory agents. Since GIACTA Trial randomized controlled trials (RCT) assigned tocilizumab (TCZ) a GC-sparing effect, higher remission rates compared to placebo potency...